Sugi Predict

Sugi Predict / Targets / MBD2

MBD2

Methyl-CpG-binding domain protein 2 · Q9UBB5 · MBD2 on Sugi Atlas →

1,278 patent compounds predicted against MBD2, 969 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6267593 SCHEMBL6267593 1.00 3/20
SCHEMBL12692358 SCHEMBL12692358 1.00 3/20
SCHEMBL12692361 SCHEMBL12692361 1.00 3/20
SCHEMBL17071969 SCHEMBL17071969 1.00 3/20
SCHEMBL6274373 SCHEMBL6274373 0.72 3/20
SCHEMBL12692474 SCHEMBL12692474 0.71 3/20
SCHEMBL6265429 SCHEMBL6265429 0.65 3/20
SCHEMBL6266559 SCHEMBL6266559 0.64 3/20
SCHEMBL9260279 SCHEMBL9260279 0.61 3/20
SCHEMBL6277272 SCHEMBL6277272 0.60 3/20
SCHEMBL9262457 SCHEMBL9262457 0.59 3/20
SCHEMBL10655998 SCHEMBL10655998 0.56 3/20
SCHEMBL6274213 SCHEMBL6274213 0.55 3/20
SCHEMBL2107839 SCHEMBL2107839 0.54 3/20
SCHEMBL18380652 SCHEMBL18380652 0.53 3/20
SCHEMBL6274214 SCHEMBL6274214 0.52 3/20
SCHEMBL10493938 SCHEMBL10493938 0.51 3/20
SCHEMBL12443345 SCHEMBL12443345 0.51 3/20
SCHEMBL6277474 SCHEMBL6277474 0.47 3/20
SCHEMBL13408297 SCHEMBL13408297 0.44 3/20

Clinical trials — most relevant to MBD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome PHASE3UNKNOWN
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC PHASE3UNKNOWN
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome PHASE1/PHASE2COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome EARLY_PHASE1ACTIVE_NOT_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer nanUNKNOWN
Analysis of DNA Methylation in Spondyloarthritis nanCOMPLETED
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. nanUNKNOWN
Exploratory Study of Rectal Mucus for Diagnosing Disease nanCOMPLETED
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
Emotional Regulation in Children With ND: the Role of Genomic Variation, Proteomic Patterns, and Early Experience nanUNKNOWN
Family Resilience Initiative Research Program nanUNKNOWN
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB) nanCOMPLETED
DNA Methylation and Autoimmune Thyroid Diseases nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity nanUNKNOWN
Diagnosis of Colorectal Cancer and Advanced Adenoma Using Cancer-specific Methylation Signatures nanUNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Patients With RETT Syndrome nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
COPENHAGEN Minipuberty Study nanUNKNOWN
Effects of Epigenetic Regulation in Chronic Pelvic Pain Syndrome nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MBD2 binder may also engage these)

ProteinNameSimilarity
Q9Z2E1 — 1.000 Q9Z2E1 →
P12755 — 0.979 P12755 →
O95983 — 0.976 O95983 →
Q9Z2D8 — 0.976 Q9Z2D8 →
Q5XKK7 — 0.975 Q5XKK7 →
O00287 — 0.975 O00287 →
Q60698 — 0.975 Q60698 →
Q9WU40 — 0.975 Q9WU40 →
Q8VCG9 — 0.974 Q8VCG9 →
Q9TUG2 — 0.974 Q9TUG2 →
P49797 — 0.973 P49797 →
Q8N228 — 0.973 Q8N228 →
B3KU38 — 0.972 B3KU38 →
Q9Z2D6 — 0.972 Q9Z2D6 →
Q6ZWB6 — 0.971 Q6ZWB6 →
Q9BUN5 — 0.971 Q9BUN5 →
Q14DQ1 — 0.971 Q14DQ1 →
Q9WU42 — 0.971 Q9WU42 →
O15079 — 0.971 O15079 →
P18444 — 0.970 P18444 →
P78524 — 0.970 P78524 →
A4FV61 — 0.970 A4FV61 →
Q50H33 — 0.970 Q50H33 →
P0DPB3 — 0.970 P0DPB3 →
Q00566 — 0.970 Q00566 →
Q99LB0 — 0.970 Q99LB0 →
P85299 — 0.969 P85299 →
P26014 — 0.969 P26014 →
Q8BXL9 — 0.969 Q8BXL9 →
A0A088MLT8 — 0.969 A0A088MLT8 →